Company profile

Silo Pharma, Inc.

Pipeline4 assets

SPC-15SPC-15 / 5-HT4 receptor agonist / Small Molecule / Psychiatry
PTSD and stress-induced anxiety disordersPreclinicalActiveGlobal
SP-26SP-26 / NMDA receptor antagonist / Implant / Neurology
Fibromyalgia and chronic painPreclinicalActiveGlobal
SPC-14SPC-14 / Unknown / Small Molecule / Neurology
Alzheimer's diseasePreclinicalActiveGlobal
SPU-16SPU-16 / Unknown / Peptide / Neurology
Multiple sclerosisPreclinicalActiveGlobal

Latest news8 items

May 7, 2026

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury ...

Apr 29, 2026

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel thera...

Apr 22, 2026

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmace...

Apr 20, 2026

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, toda...

Apr 6, 2026

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceuti...

Feb 23, 2026

Silo Pharma Announces Share Buyback Program

Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized...

Feb 18, 2026

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic t...

Dec 30, 2025

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental stage biopharmaceutical and crypto...